Wall Street analysts expect that TESARO Inc (NASDAQ:TSRO) will post earnings of ($2.62) per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for TESARO’s earnings, with estimates ranging from ($3.12) to ($2.02). TESARO reported earnings per share of ($1.28) during the same quarter last year, which suggests a negative year over year growth rate of 104.7%. The firm is expected to report its next quarterly earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that TESARO will report full-year earnings of ($8.55) per share for the current year, with EPS estimates ranging from ($10.26) to ($5.48). For the next financial year, analysts forecast that the firm will post earnings of ($3.96) per share, with EPS estimates ranging from ($7.47) to ($0.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow TESARO.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.84 million. TESARO had a negative net margin of 798.68% and a negative return on equity of 141.88%. TESARO’s revenue was up 909.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.22) earnings per share.

Several equities analysts have commented on TSRO shares. Oppenheimer Holdings Inc. started coverage on shares of TESARO in a research report on Thursday. They issued an “outperform” rating and a $183.00 price target for the company. Zacks Investment Research raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Friday, March 31st. Royal Bank of Canada raised their price target on shares of TESARO from $142.00 to $202.00 and gave the company an “outperform” rating in a research report on Friday, February 17th. FBR & Co decreased their price target on shares of TESARO from $202.00 to $200.00 and set a “mkt perform” rating for the company in a research report on Wednesday, May 10th. Finally, Cowen and Company set a $155.00 price target on shares of TESARO and gave the company a “hold” rating in a research report on Saturday, February 25th. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and an average price target of $172.86.

TESARO (NASDAQ:TSRO) traded down 2.66% during midday trading on Friday, reaching $149.11. The company’s stock had a trading volume of 675,370 shares. The stock’s 50 day moving average price is $145.05 and its 200-day moving average price is $150.07. The stock’s market cap is $8.03 billion. TESARO has a one year low of $36.71 and a one year high of $192.94.

In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $153.02, for a total transaction of $126,853.58. Following the sale, the senior vice president now directly owns 6,522 shares in the company, valued at approximately $997,996.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Edward C. English sold 229 shares of TESARO stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $177.61, for a total transaction of $40,672.69. Following the sale, the vice president now owns 625 shares in the company, valued at $111,006.25. The disclosure for this sale can be found here. Insiders have sold a total of 16,432 shares of company stock worth $2,902,602 over the last quarter. 40.50% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the company. Vident Investment Advisory LLC bought a new stake in shares of TESARO during the first quarter valued at approximately $351,000. Capital Analysts LLC bought a new stake in shares of TESARO during the fourth quarter valued at approximately $134,000. Massmutual Trust Co. FSB ADV bought a new stake in shares of TESARO during the fourth quarter valued at approximately $134,000. Meeder Asset Management Inc. bought a new stake in shares of TESARO during the first quarter valued at approximately $177,000. Finally, Soros Fund Management LLC bought a new stake in shares of TESARO during the first quarter valued at approximately $262,000. Hedge funds and other institutional investors own 98.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/05/26/tesaro-inc-tsro-expected-to-post-earnings-of-2-62-per-share.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

12 Month Chart for NASDAQ:TSRO

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.